CRL monthly performance report
Check CRL's monthly returns, drawdown, and seasonality trends — updated every month.
CRL monthly report
—
Key takeaways
- Charles River Laboratories (CRL) closed November 2026 at $337.97, down 5.97% for the month and +99.73% over the trailing 12 months.
- Year-to-date, CRL is +69.43%, outperforming the S&P 500 which has returned +10.62% YTD.
- The stock is trading +48.24% versus its 200-day moving average ($227.99), a bullish technical signal.
- Over the past three years, CRL has outperformed the S&P 500 by +27.40%, with a relative strength index reading of 116.
- Win rate over the trailing 39 months stands at 48.7% — 19 positive months versus 20 negative months.
Charles River Laboratories ended November 2026 at $337.97, posting a monthly return of −5.97%. The S&P 500 returned −0.18% over the same window, leaving relative performance at −5.79%.
The current quarter stands at +14.56% (Q4 2026 (QTD)), while medium-term trend remains constructive: price is +48.24% versus the 200-day moving average ($227.99).
Year-to-date, CRL is +69.43% against SPY +10.62%, a gap of +58.80%. The stock is currently −10.97% below its 52-week high, with maximum 3-year drawdown at −63.52%.
| Period | CRL | S&P 500 (SPY) | Excess return |
|---|---|---|---|
| 1 Day | −0.83% | −0.36% | −0.47% |
| 1 Week | +0.13% | +2.59% | −2.46% |
| 1 Month | −5.97% | −0.18% | −5.79% |
| 3 Months | +17.91% | −2.37% | +20.28% |
| 6 Months | +112.40% | +0.83% | +111.57% |
| YTD | +69.43% | +10.62% | +58.80% |
| 12 Months | +99.73% | +12.25% | +87.48% |
| 3 Years | +98.77% | +71.37% | +27.40% |
| Rank | Month | Return |
|---|---|---|
| #1 | Jun 2026 | +25.50% |
| #2 | Aug 2026 | +23.97% |
| #3 | Oct 2026 | +21.83% |
| #4 | Dec 2023 | +19.95% |
| #5 | Jul 2024 | +18.16% |
| Rank | Month | Return |
|---|---|---|
| #1 | Apr 2025 | −21.19% |
| #2 | Aug 2024 | −18.99% |
| #3 | Apr 2024 | −15.48% |
| #4 | Feb 2026 | −15.20% |
| #5 | Oct 2023 | −14.09% |
| Quarter | Return |
|---|---|
| Q3 2025 | +3.12% |
| Q4 2025 | +27.50% |
| Q1 2026 | −13.53% |
| Q2 2026 | +31.47% |
| Q3 2026 | +30.08% |
| Q4 2026 (QTD) | +14.56% |
| Year | Return |
|---|---|
| 2023 | +8.49% |
| 2024 | −21.91% |
| 2025 | +8.06% |
| 2026 | +69.43% |
| Metric | Value |
|---|---|
| 52-Week High | $379.63 (2026-10-29) |
| 52-Week Low | $146.33 (2026-02-18) |
| Current Price | $337.97 |
| 200-Day Moving Average | $227.99 |
| Price vs 200DMA | +48.24% |
| 3-Year Maximum Drawdown | −63.52% (2025-04-11) |
| Current Drawdown from 52W High | −10.97% |
| RS metric | Value |
|---|---|
| RS Index (3-year, rebased to 100) | 116 |
| 3-Year Excess Return vs S&P 500 | +27.40% |
| RS Peak | 135.9 (Mar 2024) |
| RS Trough | 48.4 (Apr 2025) |
| Status | Outperforming Benchmark |
Frequently asked questions
What was CRL's return for this report period?
CRL returned −5.97% in the latest monthly window ending 2026-11-13.
Has CRL outperformed SPY year to date?
YTD CRL: +69.43% vs SPY: +10.62%.
What is CRL's 12-month return?
+99.73% over the trailing 12 months.
Is CRL above or below its 200-day moving average?
Price is +48.24% versus 200DMA ($227.99).
What is the maximum drawdown in the 3-year window?
−63.52% on 2025-04-11.